Physician profile
David Ryon
NPI 1740230267
$4,003.52
in general payments reported to CMS, 2019-2025
33 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $567 · 2021: $612 · 2022: $332 · 2023: $258 · 2024: $712 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.24 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $724.84 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $573.94 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.15 | 2019-2024 | Ofev |
| Insmed, INC. | $373.94 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $255.15 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $191.51 | 2019-2024 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $170.33 | 2019-2021 | |
| Genzyme Corporation | $145.89 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $126.52 | 2019-2024 | Dupixent |
| Amgen INC. | $110.91 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $89.66 | 2019-2021 | |
| United Therapeutics Corporation | $84.28 | 2024-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $81.54 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Merck Sharp & Dohme LLC | $69.48 | 2022-2024 | Zerbaxa, Recarbrio, Capvaxive |
| Advanced Respiratory, INC | $49.25 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $46.06 | 2020-2023 | Cleviprex |
| Janssen Pharmaceuticals, INC | $44.75 | 2019-2020 | |
| Genentech USA, INC. | $36.69 | 2019 | |
| Csl Behring | $33.53 | 2025 | Kcentra |
| Pulmonx Corporation | $27.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.47 | 2021 | |
| Viatris Specialty LLC | $24.19 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $21.37 | 2019 | |
| Astellas Pharma US INC | $20.48 | 2019 | |
| Philips North America LLC | $19.99 | 2019 | |
| Circassia INC. | $18.90 | 2020 | |
| Shionogi INC | $17.87 | 2024 | Fetroja |
| Monaghan Medical Corporation | $17.87 | 2023 | Aerochamber |
| Gilead Sciences, INC. | $15.16 | 2021 | |
| Shire North American Group INC | $14.78 | 2019 | |
| Pfizer INC. | $13.96 | 2019 | |
| Allergan, INC. | $11.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ryon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.